Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4352W HIGH $1.96
Volume
111.95 K
Value Traded
59.98 K
Short % Float
6.31%
Days to Cover
1.0
-3.39%Week
-27.62%1 Month
-18.56%3 Month
-33.39%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.81 M
EPS (TTM)
-0.32
P/E Ratio
-
Ent. Value
1.89 M
Total Shares
18.53 M
Float Shares
16.02 M
Insiders
13.60%
Institutions
5.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BFRG Catalyst Timeline
Dated clinical, regulatory and corporate events for Bullfrog AI Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bullfrog AI Holdings, Inc.
51Total events
2Upcoming
14Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 48
▲Quarterly UpdateCorporate
Regained compliance with Nasdaq minimum stockholders' equity requirement
▲Partnership / LicenseCorporate
Commercial feasibility agreement with top 5 global pharma for MDD target identification
major depressive disordersource ↗
▲Partnership / LicenseCorporate
Commercial agreement with top 5 global pharmaceutical company
▼Equity OfferingCorporate
Financing activities via ATM and equity-line-of-credit facilities completed late March 2026
◆Oral PresentationPresentation
Abstract accepted for presentation at 2026 ASCO Gastrointestinal Cancers Symposium
oncologysource ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Sygnature Discovery to introduce BullFrog Data Networks to global biopharma clients
▲Partnership / LicenseCorporate
Commercial collaboration with Sygnature Discovery entered in Q2 2025
▲Partnership / LicenseCorporate
BullFrog AI and Eleison Pharmaceuticals enter collaboration agreement to optimize Phase 3 trial using AI
◆Partnership / LicenseCorporate
Advanced discussions with major pharma for LIBD collaboration
neuropsychiatric disorderssource ↗
▼Equity OfferingCorporate
Pricing of registered direct offering and concurrent private placement for aggregate gross proceeds of $3.13 million
▲PublicationBF-114Presentation
Publication of data supporting BF-114 in Cell Reports
liver diseases (MASLD, MASH, HCC)source ↗
▲Platform ValidationPreclinical
Identification of novel drug targets for neuropsychiatric disorders using bfLEAP platform
neuropsychiatric disorderssource ↗
◆Oral PresentationPresentation
CSO Tom Chittenden presents at Quantum Computing Symposium at Bio-IT World Conference & Expo
◆Oral PresentationPresentation
Fireside chat discussing early findings from collaboration with Lieber Institute for Brain Development
psychiatric conditionssource ↗
◆Management ChangeCorporate
Appointment of Dr. Thomas W. Chittenden as Chief Scientific Officer
▲Management ChangeCorporate
Appointment of Dr. Gwenn Smith and Dr. Jeremiah Wala to Scientific Advisory Board
▲Platform ValidationPreclinical
Early results from bfLEAP platform stratification of brain expression data
psychiatric disorderssource ↗
▲Patent GrantedBF-223IP / Competition
Australian Patent No. 2019216757 issued for novel prodrugs of mebendazole including BF-223
cancersource ↗
●Preclinical PoCBF-114Preclinical
BF-114 demonstrated compelling potential in preclinical studies
obesity, MASLD, HCCsource ↗
◆Partnership / LicenseCorporate
Initiated engagement with pharmaceutical companies for strategic partnerships
neuropsychiatric disorderssource ↗
▲Platform ValidationPreclinical
Identification of novel potential drug targets for colorectal cancer using bfLEAP platform
colorectal cancersource ↗
▲Partnership / LicenseCorporate
Target validation partnership with J. Craig Venter Institute (JCVI)
colorectal cancersource ↗
▲Preclinical PoCBF-223Preclinical
Positive preclinical data for BF-223 in glioblastoma mouse model
glioblastomasource ↗
▲Platform ValidationPreclinical
Launch of BullFrog Data Networks powered by bfLEAP platform
pan-cancersource ↗
▲Partnership / LicenseCorporate
Three-year global strategic partnership with Lieber Institute for Brain Development
neuropsychiatric disorderssource ↗
▲Partnership / LicenseCorporate
Collaboration with Lieber Institute for Brain Development announced
neuropsychiatric disorderssource ↗
▲Patent GrantedIP / Competition
USPTO to issue U.S. Patent No. 11,712,435 covering novel prodrugs of mebendazole
cancersource ↗
▲Management ChangeCorporate
Appointment of Enrique García-Rivera as Vice President of Artificial Intelligence
▲Partnership / LicenseCorporate
Expansion of worldwide license agreement with Johns Hopkins Applied Physics Laboratory for bfLEAP platform technology
▲Partnership / LicenseCorporate
Exclusive partnership with Lieber Institute for Brain Development
neuropsychiatric disorderssource ↗
▲Preclinical PoCBF-223Preclinical
Demonstrated similar efficacy of BF-223 and BF-222 in animal model of glioblastoma
glioblastomasource ↗
▲Preclinical PoCBF-222Preclinical
Demonstrated similar efficacy of BF-222 and BF-223 in animal model of glioblastoma
glioblastomasource ↗
▲Trial InitiationBF-114Trial
Initiated pre-clinical animal study for BF-114
liver disease and obesitysource ↗
▲Patent GrantedBF-223IP / Competition
Composition of matter and method of use patent for BF-223 issued by USPTO
▲Partnership / LicenseCorporate
Exclusive worldwide license from Johns Hopkins University for prodrugs of mebendazole
cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How BFRG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BFRG program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Singh VininderDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 75,000 2,442,446 held | $0.60 | 09/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BFRG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BFRG for Q2 2026. | ||||
BFRG Institutional Ownership Trends
BFRG Short Interest
Shares sold short, counted twice a month.
6.31%
Short % of Float
of tradable shares sold short
1.0M
Shares Sold Short
+36.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
5.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BFRG ranks across every disease it competes in
Competitive Position is a premium feature
See how BFRG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBFRG News
-BFRG
Oct 27, 2026▼ -3.4%today
BullFrog AI Founder and CEO Vin Singh to Deliver Keynote at AIDDD Summit
Vin Singh, CEO of BullFrog AI, will present at the AIDDD Summit on October 27, 2026. His keynote will address the advancements in AI for drug discovery, including faster timelines and cost reductions. He will also discuss the importance of AI in improving clinical outcomes and decision-making in drug development.
Read more →-BFRG
Oct 13, 2026BullFrog AI to Present at the 20th Annual LD Micro Main Event on October 20, 2026
BullFrog AI Holdings, Inc. announced that CEO Vin Singh will present at the 20th Annual LD Micro Main Event on October 20, 2026. The event will take place at the Luxe Sunset Boulevard Hotel in Los Angeles. Singh will be available for one-on-one meetings with institutional investors during the conference.
Read more →-BFRG
Oct 6, 2026▲ +16%on this news
BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder
BullFrog AI announced significant progress in its drug discovery program for major depressive disorder, achieving key milestones with a top 5 global pharmaceutical company. The company successfully identified novel therapeutic targets using its AI platform. This project is seen as a validation of BullFrog AI's technology, which may also be applied to other neuropsychiatric diseases.
Read more →-BFRG
Sep 8, 2026BullFrog AI to Participate in September 2026 Investor Conferences
BullFrog AI Holdings, Inc. will participate in two upcoming investor conferences in September 2026. CEO Vin Singh will present at the iAccess Alpha Virtual Best Ideas Fall Investment Conference and engage in a fireside chat at the Water Tower Research Insights Conference. Both events will be accessible via live webcasts.
Read more →-BFRG
Jul 22, 2026▼ -5.3%on this news
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference
BullFrog AI Holdings, Inc. will participate in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. The management team will engage in one-on-one investor meetings on July 29. The conference aims to connect healthcare companies with investors for discussions on industry trends and opportunities.
Read more →-BFRG
Jul 21, 2026BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026
BullFrog AI will participate in the Water Tower Research Fireside Chat on July 23, 2026. CEO Vin Singh will discuss the company's AI capabilities, a recent agreement with a major pharma, and its go-to-market strategy. The event is open to all investors, highlighting BullFrog's commitment to transparency and engagement.
Read more →-BFRG
Jun 2, 2026▲ +9.6%on this news
BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
BullFrog AI has announced the formation of a new commercial leadership team aimed at accelerating growth for its AI-driven drug discovery platform. The team consists of seasoned executives with extensive experience in technology sales, business development, and scientific operations. Their combined expertise is expected to enhance BullFrog AI's commercial initiatives and expand its business pipeline.
Read more →-BFRG
Apr 22, 2026▼ -6.5%on this news· ran to -17% by day 3
Bullfrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement balance sheet provides capital runway into late 2027
BullFrog AI Holdings, Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, as confirmed by a notification received on April 21, 2026. This compliance was achieved through recent sales under their existing financial facilities. The company has also secured a commercial agreement with a major pharmaceutical player, enhancing its credibility in the market. However, they will be monitored for one year, and failure to maintain compliance could lead to severe consequences, including delisting.
Read more →-BFRG
Apr 14, 2026BullFrog AI Announces Participation at AACR Annual Meeting
BullFrog AI Holdings, Inc. announced its participation as an exhibitor at the AACR Annual Meeting 2026 in San Diego, California. The event, running from April 17-22, will gather leaders in cancer research to discuss advancements in oncology. BullFrog AI aims to leverage AI to enhance drug discovery and development.
Read more →-BFRG
Apr 13, 2026▲ +18.6%on this news
Bullfrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners
BullFrog AI Holdings, Inc. announced a business update highlighting its strengthened balance sheet and execution capabilities. The company closed its first commercial feasibility agreement with a top 5 global pharmaceutical company, focusing on drug targets for major depressive disorder. This agreement underscores the company's active role in transforming pharmaceutical R&D through its AI technology, validated by a significant upfront milestone payment structure. BullFrog aims to expand its commercial activities with additional partnerships and collaborations in the biotech space.
Read more →-BFRG
Mar 30, 2026▲ +106.6%on this news· ran to +231% by day 1
Bullfrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive agreement serves as high-profile third party validation of BullFrog AI's proprietary capabilities
BullFrog AI has entered into a commercial agreement with a leading global pharmaceutical company to utilize its bfLEAP platform for identifying therapeutic targets in major depressive disorder (MDD). This partnership serves as a strong validation of BullFrog AI's AI-driven capabilities in drug discovery and development. The MDD market, which was valued at over $8 billion in 2025, is expected to experience substantial growth, indicating promising prospects for the collaboration. The CEO expressed confidence that this relationship may expand to other research areas within the customer's portfolio.
Read more →-BFRG
Dec 30, 2025Bullfrog AI Publishes Annual Letter to Shareholders significant progress in 2025 and outlines commercial priorities and potential catalysts entering 2026
BullFrog AI Holdings, Inc. has released its annual letter to shareholders, highlighting significant advancements made in 2025 and outlining strategic priorities for 2026. The company has engaged in key collaborations with notable pharmaceutical organizations and evidenced successful deployment of its technology within clinical development, particularly in oncology. BullFrog AI's ongoing discussions and commercial partnerships suggest a promising path for growth and transformative opportunities in the upcoming year. Furthermore, the introduction of their AI-powered data preparation tool, bfPREP, marks a significant innovation aimed at optimizing the drug development process.
Read more →-BFRG
Jun 12, 2025Bullfrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks to Global Biopharma Clients
BullFrog AI has announced a strategic collaboration with Sygnature Discovery, which will facilitate the introduction of BullFrog Data Networks to Sygnature's global biopharma clients. This partnership is expected to significantly boost BullFrog AI's brand recognition and projected revenues, potentially generating between $15-$30 million through 2028. BullFrog Data Networks utilizes AI to enhance drug discovery processes, enabling researchers to analyze complex biological data efficiently. However, there are risks associated with reliance on Sygnature's marketing efficacy and market competition.
Read more →-BFRG
Feb 27, 2025▼ -5.3%on this news· ran to -27% by day 3
Bullfrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial to leverage BullFrog Data NetworksTM to enhance patient clustering and safety analysis in glufosfamide clinical trials
BullFrog AI and Eleison Pharmaceuticals have announced a collaboration agreement to optimize Eleison's Phase 3 clinical trials of glufosfamide, a treatment for pancreatic cancer. BullFrog AI will leverage its Data Networks and bfLEAP AI technology to improve trial efficiency and patient insights. The partnership aims to enhance patient clustering and safety analysis, potentially accelerating the market entry of the therapies in Eleison's oncology pipeline. The trial for glufosfamide is anticipated to be completed by 2027.
Read more →-BFRG
Dec 27, 2024BullFrog AI Issues Letter to Stockholders GAITHERSBURG, Md.
BullFrog AI Holdings, Inc. issued a letter to stockholders highlighting its significant progress in AI-driven drug development throughout 2024. The company has advanced its proprietary bfLEAP platform and established collaborations, particularly with the Lieber Institute for Brain Development, yielding insights into neuropsychiatric disorders. Additionally, BullFrog announced the expansion of research on its promising drug candidate BF-114 and strengthened its intellectual property portfolio with new patent protections. With a robust cash position and the addition of key experts to its team, the outlook for 2025 is optimistic.
Read more →-BFRG
Dec 17, 2024▲ +9.8%on this news
BullFrog AI Announces Appointment of Chief Financial Officer GAITHERSBURG, Md.
BullFrog AI Holdings, Inc. has announced the appointment of Josh Blacher as its Chief Financial Officer following the death of former CFO Dane Saglio. Blacher brings over two decades of financial experience within the life science sector, indicating strong potential for advancing the company's financial strategy. His role is pivotal as BullFrog AI aims to leverage artificial intelligence in drug development amidst a transition period characterized by the loss of a key leader.
Read more →-BFRG
Oct 18, 2024▼ -5.8%on this news
Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million GAITHERSBURG, Md.
Bullfrog AI Holdings, Inc. has announced a registered direct offering and concurrent private placement expected to yield aggregate gross proceeds of $3.13 million. The deal involves the sale of 1,565,000 shares of common stock at a purchase price of $2.00 each, accompanied by warrants to buy an equal number of shares. The closing of this offering is slated for approximately October 21, 2024, pending customary closing conditions. The capital raised is part of Bullfrog's strategy to further advance its technology-enabled drug development initiatives.
Read more →-BFRG
Oct 15, 2024BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni GAITHERSBURG, Md.
BullFrog AI has appointed Dr. John Baldoni, a seasoned veteran from GSK, to its Scientific Advisory Board. Dr. Baldoni brings over 40 years of pharmaceutical experience, particularly in drug discovery and development. His leadership and insights are anticipated to enhance the company's innovative efforts, specifically in the commercialization of the bfLEAP platform, which utilizes AI for drug development. Dr. Baldoni expressed enthusiasm about collaborating with BullFrog AI to leverage AI technologies in improving drug discovery.
Read more →-BFRG
Oct 9, 2024BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114 - The study, led by Dr. Lopa Mishra and published in Cell Reports, provides new mechanistic evidence for role of
BullFrog AI has published new research in Cell Reports regarding its liver disease treatment candidate, BF-114. The study, led by Dr. Lopa Mishra, suggests that BF-114 may effectively target 2-spectrin to prevent the progression of liver diseases such as MASLD, MASH, and HCC. This research reinforces previous findings and highlights the potential of BF-114 to address unmet medical needs in treating obesity-related liver conditions. Dr. Mishra's expertise will support the continued development of BF-114 as BullFrog AI aims to explore various therapeutic applications.
Read more →-BFRG
Jul 25, 2024▲ +15.4%on this news
BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets Discussions underway for drug target discovery deals with potential pharma partners GAI
BullFrog AI Holdings, Inc. announced advancements in its collaboration with the Lieber Institute for Brain Development, focusing on bipolar disorder. New analysis has identified specific molecular pathways and gene clusters linked to the condition, which could enable the development of targeted therapeutics. The findings indicate significant involvement of various brain regions, leading to hopes for more effective treatments. The company plans to validate these discoveries further and collaborate with pharmaceutical partners to enhance drug target discovery.
Read more →About Bullfrog AI Holdings, Inc.
Headquarters325 ELLINGTON BLVD., GAITHERSBURG, MD, 20878
BIOPHARMAWATCH ELITE PLUS
Trade the next BFRG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime